GSK gears up for phase 3 with mRNA flu vaccine after promising phase 2 data

GSK reports its mRNA influenza vaccine candidates elicited higher immune responses than standard and high-dose vaccines in a 971-participant phase 2 trial, with acceptable safety. The company plans a phase 3 study this month for the optimized FLUm3HA.b-3NA candidate (targeting HA and NA), aiming to boost its faltering flu business amid a market historically characterized by variable vaccine effectiveness. Moderna’s recent FDA approval of an mRNA flu vaccine underscores the growing role of mRNA approaches in flu protection.